The growing prevalence of sepsis, the increasing burden of hospital-acquired infections, the growing number of cases of pneumonia, the increase in the number of sepsis interventions and the increase in support for sepsis-related scientific research are the key reasons for the growth of the demand for sepsis diagnostics. In hospitalized patients, the most frequent complications are hospital-acquired infections. Sepsis impacts over 30 million people worldwide, and over 6 million deaths per year are caused by sepsis, according to statistics released by the WHO in April 2018. According to the same results, every year, about 3 million newborns and 1.2 million children suffer from this disease.
In hospitals, sepsis affects major patient groups and is the sixth most important cause for hospitalisation. In contemporary healthcare, fast and precise profiling of infection-causing pathogens remains a major obstacle. In addition, in the selection of effective antibiotic therapy as part of the procedure, recognition of the causative pathogen is important. Such criteria make molecular diagnostics (MDx) an appealing technique for the diagnosis of sepsis.
Thanks to their simple viability and precision of detection methods, molecular diagnostics has drawn many international corporations and universities. The gold standard for the molecular diagnostic approach was blood culture analysis for quick and detailed profiling of pathogens. However, relative to traditional methods, the cost of molecular diagnostics has remained very high, which limits its market expansion.
In the current situation, it will take up to 72 hours or longer to process and produce data for any of the existing sepsis diagnostic tests. Also there is a strong unmet demand for early detection of this life-threatening disease in the marketplace for more effective and fast diagnostic testing that can save thousands of lives. Regulatory acceptance and the development of technologically innovative diagnostic technologies to exploit unmet opportunities have also increased.
Adroit Market Research study on the global market for sepsis diagnostics offers a holistic view of the industry from 2020 to 2028 as forecast period, including factors such as market drivers, limitations, opportunities, threats and regulatory overview. The market has been analyzed from 2018 to 2028, with a base year estimate of 2019 and a projection from 2020 to 2028. The report covers the current status and potential characteristics of the market at both the global and the country level. Moreover, the report also assesses market competition with Porter's analysis of five strengths and places leading players on the basis of their product range, regional presence, strategic initiatives and overall sales. Prominent players in the global composite resin market have been analyzed in depth.
Key vendors in the market include bioMérieux SA, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Luminex Corporation, Epic Systems Corporation, Koninklijke Philips N.V., Koninklijke Philips N.V., and many more
Key Segments of the Global sepsis diagnostics Market
Product Overview, 2018-2028 (USD Million)
- Blood Culture Media
- Assay Kits and Reagents
Technology Overview, 2018-2028 (USD Million)
- Molecular Diagnostics
- Flow Cytometry
Pathogen Overview, 2018-2028 (USD Million)
- Bacterial Sepsis
- Fungal Sepsis
Testing Type Overview, 2018-2028 (USD Million)
- Laboratory Testing
- PoC Testing
Regional Overview, 2018-2028 (USD Million)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia-Pacific
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
- South America
- Rest of South America